Addex Therapeutics leads CHF 2 million investment in Stalicla to advance precision medicine in neuropsychiatric ...
Addex Therapeutics, a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company …